Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Oncogene ; 36(36): 5110-5121, 2017 09 07.
Artículo en Inglés | MEDLINE | ID: mdl-28481878

RESUMEN

The MAPK pathway is activated in the majority of melanomas and is the target of therapeutic approaches. Under normal conditions, it initiates the so-called immediate early response, which encompasses the transient transcription of several genes belonging to the AP-1 transcription factor family. Under pathological conditions, such as continuous MAPK pathway overactivation due to oncogenic alterations occurring in melanoma, these genes are constitutively expressed. The consequences of a permanent expression of these genes are largely unknown. Here, we show that FOSL1 is the main immediate early AP-1 member induced by melanoma oncogenes. We first examined its role in established melanoma cells. We found that FOSL1 is involved in melanoma cell migration as well as cell proliferation and anoikis-independent growth, which is mediated by the gene product of its target gene HMGA1, encoding a multipotent chromatin modifier. As FOSL1 expression is increased in patient melanoma samples compared to nevi, we investigated the effect of enhanced FOSL1 expression on melanocytes. Intriguingly, we found that FOSL1 acts oncogenic and transforms melanocytes, enabling subcutaneous tumor growth in vivo. During the process of transformation, FOSL1 reprogrammed the melanocytes and downregulated MITF in a HMGA1-dependent manner. At the same time, AXL was upregulated, leading to a shift in the MITF/AXL balance. Furthermore, FOSL1 re-enforced pro-tumorigenic transcription factors MYC, E2F3 and AP-1. Together, this led to the enhancement of several growth-promoting processes, such as ribosome biogenesis, cellular detachment and pyrimidine metabolism. Overall, we demonstrate that FOSL1 is a novel reprogramming factor for melanocytes with potent tumor transformation potential.


Asunto(s)
Transformación Celular Neoplásica/patología , Regulación Neoplásica de la Expresión Génica , Melanocitos/patología , Melanoma/patología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Neoplasias Cutáneas/patología , Factor de Transcripción AP-1/metabolismo , Movimiento Celular , Proliferación Celular , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Células Cultivadas , Perfilación de la Expresión Génica , Proteína HMGA1a/genética , Proteína HMGA1a/metabolismo , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Melanocitos/metabolismo , Melanoma/genética , Melanoma/metabolismo , Factor de Transcripción Asociado a Microftalmía/genética , Factor de Transcripción Asociado a Microftalmía/metabolismo , Nevo/genética , Nevo/metabolismo , Nevo/patología , Proteínas Proto-Oncogénicas c-fos/genética , Transducción de Señal , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/metabolismo , Factor de Transcripción AP-1/genética , Activación Transcripcional
2.
Cell Death Dis ; 6: e1711, 2015 Apr 02.
Artículo en Inglés | MEDLINE | ID: mdl-25837487

RESUMEN

Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle arrest frequently characterized by a bi- or multinuclear phenotype that is considered as a barrier to cancer progression. However, the long-sustained conviction that senescence is a truly irreversible process has recently been challenged. Still, it is not known whether cells driven into OIS can progress to cancer and thereby pose a potential threat. Here, we show that prolonged expression of the melanoma oncogene N-RAS(61K) in pigment cells overcomes OIS by triggering the emergence of tumor-initiating mononucleated stem-like cells from senescent cells. This progeny is dedifferentiated, highly proliferative, anoikis-resistant and induces fast growing, metastatic tumors. Our data describe that differentiated cells, which are driven into senescence by an oncogene, use this senescence state as trigger for tumor transformation, giving rise to highly aggressive tumor-initiating cells. These observations provide the first experimental in vitro evidence for the evasion of OIS on the cellular level and ensuing transformation.


Asunto(s)
Melanocitos/patología , Células Madre Neoplásicas/patología , Secuencia de Aminoácidos , Animales , Proliferación Celular/fisiología , Senescencia Celular/fisiología , GTP Fosfohidrolasas/metabolismo , Xenoinjertos , Humanos , Técnicas In Vitro , Melanocitos/metabolismo , Proteínas de la Membrana/metabolismo , Ratones , Ratones Desnudos , Datos de Secuencia Molecular , Células Madre Neoplásicas/metabolismo , Nevo/metabolismo , Nevo/patología , Transducción de Señal
3.
Oncogene ; 33(6): 771-82, 2014 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-23353821

RESUMEN

The development of malignant melanoma is a highly complex process, which is still poorly understood. A majority of human melanomas are found to express a few oncogenic proteins, such as mutant RAS and BRAF variants. However, these oncogenes are also found in nevi, and it is now a well-accepted fact that their expression alone leads to senescence. This renders the understanding of senescence escape mechanisms an important point to understand tumor development. Here, we approached the question of senescence evasion by expressing the transcription factor v-myc myelocytomatosis viral oncogene homolog (c-MYC), which is known to act synergistically with many oncogenes, in melanocytes. We observed that MYC drives the evasion of reactive-oxygen stress-induced melanocyte senescence, caused by activated receptor tyrosine kinase signaling. Conversely, MIZ1, the growth suppressing interaction partner of MYC, is involved in mediating melanocyte senescence. Both, MYC overexpression and Miz1 knockdown led to a strong reduction of endogenous reactive-oxygen species (ROS), DNA damage and senescence. We identified the cystathionase (CTH) gene product as mediator of the ROS-related MYC and MIZ1 effects. Blocking CTH enzymatic activity in MYC-overexpressing and Miz1 knockdown cells increased intracellular stress and senescence. Importantly, pharmacological inhibition of CTH in human melanoma cells also reconstituted senescence in the majority of cell lines, and CTH knockdown reduced tumorigenic effects such as proliferation, H2O2 resistance and soft agar growth. Thus, we identified CTH as new MYC target gene with an important function in senescence evasion.


Asunto(s)
Cistationina gamma-Liasa/biosíntesis , Melanocitos/enzimología , Melanocitos/patología , Melanoma/enzimología , Melanoma/patología , Senescencia Celular/fisiología , Cistationina gamma-Liasa/genética , Cistationina gamma-Liasa/metabolismo , Daño del ADN , Humanos , Melanocitos/metabolismo , Melanoma/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal , Neoplasias Cutáneas , Melanoma Cutáneo Maligno
4.
Oncogene ; 32(19): 2403-11, 2013 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-22751127

RESUMEN

The epidermal growth factor (EGF) receptor (EGFR) has a key role in normal embryonic development, adult tissue homeostasis and many pathological processes, in particular tumour formation. Aberrant EGFR activation occurs in many cancer types, and inhibition of this receptor is a promising anti-tumour strategy. Besides overexpression of the wild-type receptor, mutated oncogenic EGFR variants are often associated with malignant transformation. In human non-small-cell lung cancers, kinase mutants of the EGFR are rather common. Human glioblastoma often express the truncated EGFRvIII version as well as other dimerized and permanently activated mutants of the receptor, which are considered as tumour drivers. Similarly, the mutated and dimerized EGFR variant Xiphophorus melanoma receptor kinase (Xmrk) is causative for the development of malignant pigment cell tumours in medaka and Xiphophorus melanoma models. It is generally believed that oncogenic receptors that are active due to dimerizing mutations are ligand independent. Here, we show that different EGFR variants from fish and human efficiently induce autocrine loops by inducing EGFR ligands such as amphiregulin and HB-EGF. Importantly, the pre-dimerized oncogenic EGFR versions Xmrk from Xiphophorus and human EGFR(C600F), though already active in absence of ligands, respond to ligand stimulation with enhanced oncogenic signalling. In summary, our data show that autocrine or paracrine loops are still acting on pre-dimerized oncogenic EGFRs and contribute to their pro-tumorigenic signalling.


Asunto(s)
Receptores ErbB/metabolismo , Adulto , Animales , Animales Modificados Genéticamente , Comunicación Autocrina , Ciprinodontiformes , Activación Enzimática , Receptores ErbB/química , Receptores ErbB/genética , Humanos , Melanocitos/citología , Melanocitos/enzimología , Ratones , Modelos Moleculares , Multimerización de Proteína , Transducción de Señal
6.
Oncogene ; 27(56): 7070-82, 2008 Nov 27.
Artículo en Inglés | MEDLINE | ID: mdl-18806824

RESUMEN

Contrary to malignant melanoma, nevi are a benign form of melanocytic hyperproliferation. They are frequently observed as precursor lesions of melanoma, but they also feature biochemical markers of senescence. In particular, evidence for oncogene-induced melanocyte senescence as natural means to prevent tumorigenesis has been obtained in nevi with mutated B-Raf(V600E). Here, we demonstrate that strong oncogenic growth factor receptor signalling drives melanocytes into senescence, whereas weaker signals keep them in the proliferative state. Activation of oncogene-induced senescence also produces multinucleated giant cells, a long known histological feature of nevus cells. The protein levels of the senescence mediators, p53 and pRB, and their upstream activators do not correlate with senescence. However, strong oncogene signalling leads to pronounced reactive oxygen stress, and scavenging of reactive oxygen species (ROS) efficiently prevents the formation of multinucleated cells and senescence. Similarly, expression of oncogenic N-RAS results in ROS generation, DNA damage and the same multinuclear senescent phenotype. Hence, we identified oncogenic signalling-dependent ROS production as critical mediator of the melanocytic multinuclear phenotype and senescence, both of them being hallmarks of human nevus cells.


Asunto(s)
Melanocitos/metabolismo , Nevo/genética , Nevo/metabolismo , Oncogenes/genética , Oxígeno/metabolismo , Especies Reactivas de Oxígeno , Proliferación Celular , Senescencia Celular , Daño del ADN , Doxiciclina/farmacología , Humanos , Neoplasias/metabolismo , Fenotipo , Proteína de Retinoblastoma/metabolismo , Transducción de Señal , Proteína p53 Supresora de Tumor/metabolismo
8.
Protoplasma ; 217(1-3): 43-9, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11732337

RESUMEN

Plasmodium falciparum is the causative agent of malaria tropica. Due to the increasing resistance towards the commonly used plasmodicidal drugs there is an urgent need to identify and assess new targets for the chemotherapeutic intervention of parasite development in the human host. It is established that P. falciparum-infected erythrocytes are vulnerable to oxidative stress, and therefore efficient antioxidative systems are required to ensure parasite development within the host cell. The thioredoxin and glutathione redox systems represent two powerful means to detoxify reactive oxygen species and this article summarizes some of the recent work which has led to a better understanding of these systems in the parasite and will help to assess them as potential targets for the development of new chemotherapeutics of malaria.


Asunto(s)
Antimaláricos/farmacología , Glutatión/metabolismo , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/metabolismo , Tiorredoxinas/metabolismo , Animales , Cloroquina/farmacología , Resistencia a Medicamentos , Eritrocitos/metabolismo , Eritrocitos/parasitología , Humanos , Malaria Falciparum , Oxidación-Reducción , Plasmodium falciparum/enzimología , Reductasa de Tiorredoxina-Disulfuro/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...